We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Unisys
UIS
$252M
| $371K | 0.19% |
134,338
+124,283
| +1,236% | +$388K |
|
152
Iridium Communications
IRDM
$4.82B
| $370K | 0.19% |
+21,298
| New | +$376K |
|
153
Heartland Express
HTLD
$1.05B
| $370K | 0.19% |
+40,960
| New | +$341K |
|
154
QuinStreet
QNST
$919M
| $368K | 0.19% |
25,617
+8,507
| +50% | +$123K |
|
155
Aflac
AFL
$65.7B
| $367K | 0.19% |
+3,331
| New | +$367K |
|
156
Lemonade
LMND
$4.84B
| $367K | 0.19% |
5,152
+1,158
| +29% | +$77.8K |
|
157
Johnson & Johnson
JNJ
$650B
| $367K | 0.19% |
+1,771
| New | +$350K |
|
158
Phreesia
PHR
$662M
| $366K | 0.19% |
21,636
+6,982
| +48% | +$144K |
|
159
Euroseas
ESEA
$532M
| $366K | 0.19% |
6,696
-1,579
| -19% | -$90.7K |
|
160
Rush Street Interactive
RSI
$3.22B
| $365K | 0.18% |
+18,798
| New | +$347K |
|
161
Newell Brands
NWL
$2.22B
| $363K | 0.18% |
97,485
+81,059
| +493% | +$327K |
|
162
Bloomin' Brands
BLMN
$735M
| $362K | 0.18% |
+58,603
| New | +$408K |
|
163
Hanover Insurance
THG
$7.81B
| $362K | 0.18% |
+1,978
| New | +$356K |
|
|
NIU
164
Niu Technologies
NIU
$211M
| $361K | 0.18% |
+119,283
| New | +$462K |
|
165
SI-BONE Inc
SIBN
$789M
| $361K | 0.18% |
18,318
-10,981
| -37% | -$191K |
|
|
MRSH
166
Marsh
MRSH
$90.3B
| $361K | 0.18% |
1,944
+637
| +49% | +$119K |
|
167
Kirby Corp
KEX
$7.69B
| $360K | 0.18% |
+3,270
| New | +$332K |
|
168
Myriad Genetics
MYGN
$503M
| $360K | 0.18% |
+58,497
| New | +$424K |
|
169
Roku
ROKU
$21.4B
| $360K | 0.18% |
3,315
-113
| -3% | -$11.5K |
|
170
Real Brokerage
REAX
$392M
| $359K | 0.18% |
98,484
+38,893
| +65% | +$150K |
|
171
HF Sinclair
DINO
$16.1B
| $359K | 0.18% |
7,793
+3,238
| +71% | +$167K |
|
|
GDEN
172
DELISTED
Golden Entertainment
GDEN
| $359K | 0.18% |
+13,196
| New | +$342K |
|
173
Futu Holdings
FUTU
$14.3B
| $359K | 0.18% |
2,184
+412
| +23% | +$70.7K |
|
174
Webster Financial
WBS
$12.5B
| $359K | 0.18% |
+5,696
| New | +$338K |
|
175
Astera Labs
ALAB
$45.8B
| $358K | 0.18% |
+2,154
| New | +$360K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.